Out to Do Things Differently

At Kallyope, we focus on big health challenges that matter to patients and families. We aim to discover and develop effective, easy to use, and well-tolerated oral agents addressing metabolic, neurological, and gastrointestinal diseases.

Based in New York City, we are home to some of the world’s most intrepid scientific minds from the world’s top institutions, working alongside a seasoned team with a proven track record of success in drug discovery and development.

Board of Directors

Franz Humer, Ph.D.

Chair, Board of Directors

Jay Galeota

CEO & President, Kallyope

Jeff Goater

The Column Group

Peter Hecht, Ph.D.

Tisento Therapeutics

Tom Maniatis, Ph.D.

Columbia University

William Rieflin


Amy Schulman

Polaris Partners

Nancy Thornberry

Founding CEO, Kallyope

Josh Wolfe

Lux Capital

Strategic Advisors

Tony Evnin, Ph.D.
Terry McGuire

Scientific Advisory Board